Literature DB >> 33530243

Complementary and alternative therapies for non-alcoholic fatty liver disease: A Bayesian network meta-analysis protocol.

Tiefeng Zhang1,2, Duan Han2, Tianqi Zhang1, Cai Jing2, Jianguang Sun3.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has become a global pandemic, and its incidence is increasing year by year. At present, there are no definite curative drugs for the treatment of NAFLD in modern medicine. Surprisingly, complementary and alternative therapies play an important role and have special advantages. In this study, we will adopt Bayesian network meta-analysis (NMA) to evaluate the efficiency and safety of complementary therapy and alternative therapies for NAFLD.
METHODS: We will collect randomized controlled trials (RCTs) related to the treatment of NAFLD in PubMed, Cochrane Library, CNKI, and other databases. Two reviewers will screen the literature and extract data in line with the inclusion and exclusion criteria, and then assess the risk of bias according to Cochrane risk of bias assessment tool. The Bayesian NMA will be performed by Stata16.0 and WinBUGS1.4.3.
RESULTS: Our study will compare and rank the efficacy and safety of diverse complementary and alternative therapies for NAFLD.
CONCLUSION: This study can provide credible evidence for the efficacy and safety of complementary therapies and alternative therapies in the treatment of NAFLD. We expect to assist clinicians and patients to choose the optimal therapeutic regimen. PROTOCOL REGISTRATION NUMBER: INPLASY2020120136.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Year:  2021        PMID: 33530243      PMCID: PMC7850717          DOI: 10.1097/MD.0000000000024432

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  23 in total

Review 1.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

2.  A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis.

Authors:  Milo A Puhan; Holger J Schünemann; Mohammad Hassan Murad; Tianjing Li; Romina Brignardello-Petersen; Jasvinder A Singh; Alfons G Kessels; Gordon H Guyatt
Journal:  BMJ       Date:  2014-09-24

Review 3.  Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation.

Authors:  Parvin Farzanegi; Amir Dana; Zeynab Ebrahimpoor; Mahdieh Asadi; Mohammad Ali Azarbayjani
Journal:  Eur J Sport Sci       Date:  2019-02-08       Impact factor: 4.050

Review 4.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Authors:  Zobair Younossi; Frank Tacke; Marco Arrese; Barjesh Chander Sharma; Ibrahim Mostafa; Elisabetta Bugianesi; Vincent Wai-Sun Wong; Yusuf Yilmaz; Jacob George; Jiangao Fan; Miriam B Vos
Journal:  Hepatology       Date:  2019-06       Impact factor: 17.425

5.  Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Qing Ye; Biyao Zou; Yee Hui Yeo; Jie Li; Daniel Q Huang; Yuankai Wu; Hongli Yang; Chuanli Liu; Leslie Y Kam; Xiang Xuan Eunice Tan; Nicholas Chien; Sam Trinh; Linda Henry; Christopher Donald Stave; Tetsuya Hosaka; Ramsey C Cheung; Mindie H Nguyen
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-05-12

6.  Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis.

Authors:  Minhua Lin; Huamin Zeng; Guiqing Deng; Jiapei Lei; Jinxin Li
Journal:  Clin Res Hepatol Gastroenterol       Date:  2020-12-04       Impact factor: 2.947

7.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.

Authors:  Larissa Shamseer; David Moher; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart
Journal:  BMJ       Date:  2015-01-02

Review 8.  Current status, problems, and perspectives of non-alcoholic fatty liver disease research.

Authors:  Naoki Tanaka; Takefumi Kimura; Naoyuki Fujimori; Tadanobu Nagaya; Michiharu Komatsu; Eiji Tanaka
Journal:  World J Gastroenterol       Date:  2019-01-14       Impact factor: 5.742

Review 9.  Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects.

Authors:  Tea L Laursen; Christoffer A Hagemann; Chunshan Wei; Konstantin Kazankov; Karen L Thomsen; Filip K Knop; Henning Grønbæk
Journal:  World J Hepatol       Date:  2019-02-27

Review 10.  Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?

Authors:  Chencheng Xie; Dina Halegoua-DeMarzio
Journal:  Nutrients       Date:  2019-11-19       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.